Epilepsy is a disabling neurological disorder that is characterized by recurring, unprovoked seizures. Drug-resistant epilepsy affects approximately 30% of individuals with epilepsy; thus, one of the main challenges for epilepsy therapy is the development of alternative anticonvulsant approaches. The discovery that inflammatory mediators contribute significantly to the onset and recurrence of seizures in experimental models, as well as the presence of inflammatory molecules in human epileptogenic tissue, highlight the possibility of targeting specific inflammation-related pathways to control seizures that are otherwise resistant to the available anti-epileptic drugs. This review summarizes the proof-of-principle evidence, obtained in experimental disease models, demonstrating the anticonvulsant activity of specific anti-inflammatory drugs, such as inhibitors of IL-1-converting enzyme/caspase 1 and antagonists of IL-1β receptors. Drugs that block IL-1β actions have entered clinical trials as potential therapeutics for autoimmune and inflammatory pathologies, and may also have therapeutic potential in epilepsies associated with proinflammatory processes in the brain.
|Number of pages||8|
|Journal||Current Opinion in Investigational Drugs|
|Publication status||Published - Jan 2010|
- IL-1-converting enzyme/caspase 1
- IL-1b receptor
ASJC Scopus subject areas
- Drug Discovery